When anti–tumor necrosis factor-alpha (anti-TNF) treatment fails to achieve remission for patients with ulcerative colitis (UC), tofacitinib (Xeljanz) appears more effective sooner than vedolizumab ...

Both tofacitinib regimens were noninferior compared with ciclosporin for the primary efficacy end point... The oral Janus kinase inhibitor, tofacitinib, is safe and effective in low-to-moderate risk ...

Human colon, illustration. Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure. For patients with ulcerative colitis (UC) ...

The appraisal committee considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG) and responses from stakeholders. See the committee papers for full ...

Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to ...

XELJANZ/XELJANZ XR (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to ...

The evaluation committee considered evidence submitted by Pfizer, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...

Favorable outcomes were observed among patients with vitiligo who received systemic Janus kinase inhibitors, with tofacitinib associated with the highest rate of complete resolution. Tofacitinib may ...

Anti–melanoma differentiation–associated protein (MDA) 5 (anti-MDA5)–positive amyopathic dermatomyositis (ADM)–associated interstitial lung disease (ILD) (hereafter, ADM-ILD) is a rapidly progressive ...

Current treatment options for ulcerative colitis are limited, and many patients do not respond to existing medications. Published in The New England Journal of Medicine, the findings from three phase ...

A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.